Department of Neonatal Intensive Care, Women and Children's Division, Oslo University Hospital, Rikshospitalet, Norway; Department of Nutrition, Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Norway.
Department of Food and Safety and Infection Biology, Norwegian University of Life Science, Oslo, Norway.
Environ Int. 2016 Apr-May;89-90:228-34. doi: 10.1016/j.envint.2016.01.024. Epub 2016 Feb 26.
Very low birth weight infants (VLBW; birth weight<1500g) are exposed to potentially harmful phthalates from medical devices during their hospital stay. We measured urinary phthalate concentrations among hospitalized VLBW infants participating in a nutritional study. Possible associations between different phthalates and birth weight (BW), septicemia and bronchopulmonary dysplasia (BPD) were evaluated. Forty-six VLBW infants were enrolled in this randomized controlled nutritional study. The intervention group (n=24) received increased quantities of energy, protein, fat, essential fatty acids and vitamin A, as compared to the control group (n=22). The concentrations of 12 urinary phthalate metabolites were measured, using high-performance liquid chromatography coupled to tandem mass spectrometry, at 3 time points during the first 5weeks of life. During this study, the levels of di (2-ethylhexyl) phthalate (DEHP) metabolites decreased, whereas an increasing trend was seen regarding metabolites of di-iso-nonyl phthalate (DiNP). Significantly higher levels of phthalate metabolites were seen in infants with lower BW and those diagnosed with late onset septicemia or BPD. A significant positive correlation between the duration of respiratory support and DEHP metabolites was observed (p≤0.01) at 2.9weeks of age. Birth weight was negatively associated with urinary phthalate metabolite concentrations. Infants with lower BW and those diagnosed with septicemia or BPD experienced prolonged exposure from medical equipment containing phthalates, with subsequent higher levels of phthalate metabolites detected. Clinical Trial Registration no.: NCT01103219.
极低出生体重儿(VLBW;出生体重<1500g)在住院期间会接触到来自医疗设备的潜在有害邻苯二甲酸酯。我们测量了参与营养研究的住院 VLBW 婴儿的尿邻苯二甲酸酯浓度。评估了不同邻苯二甲酸酯与出生体重(BW)、败血症和支气管肺发育不良(BPD)之间的可能关联。46 名极低出生体重儿参与了这项随机对照营养研究。与对照组(n=22)相比,干预组(n=24)接受了更多的能量、蛋白质、脂肪、必需脂肪酸和维生素 A。在生命的前 5 周内的 3 个时间点,使用高效液相色谱-串联质谱法测量了 12 种尿邻苯二甲酸酯代谢物的浓度。在这项研究中,二(2-乙基己基)邻苯二甲酸酯(DEHP)代谢物的水平下降,而二异壬基邻苯二甲酸酯(DiNP)代谢物的水平呈上升趋势。BW 较低和诊断为晚发性败血症或 BPD 的婴儿的邻苯二甲酸酯代谢物水平明显较高。在 2.9 周龄时,观察到呼吸支持时间与 DEHP 代谢物之间存在显著正相关(p≤0.01)。BW 与尿邻苯二甲酸酯代谢物浓度呈负相关。BW 较低和诊断为败血症或 BPD 的婴儿接触含有邻苯二甲酸酯的医疗设备时间较长,随后检测到的邻苯二甲酸酯代谢物水平较高。临床试验注册号:NCT01103219。